The customer is a private healthcare provider that is acquiring their first Nexstim system.
So it’s probably not Terveystalo then, which is a positive thing. Terveystalo will almost certainly order devices with the Recuror acquisition, but now it seems other companies have also become active, as I expected.
It’s a shame we don’t know the customer yet, but now we’ll keep a close eye on Mehiläinen, Aava, Pihlajalinna, and other companies regarding their service offerings.
Yep, exactly! When Nexstim announces that a “system” has been sold, can it also mean more than one device? Or are larger deals announced differently? Of course, here, Mehiläinen, Pihlajalinna, Aava, etc., will probably start cautiously with one device in the Helsinki metropolitan area and then monitor if there is demand for this and how profitable the business is. I bet it’s Mehiläinen
"With NBS 6, Nexstim’s unique E-field navigated TMS technology can be used more easily than ever before. Part of this new product generation is an easy-to-use, software-driven application and modular product design, which allows the system’s features to expand over time and be highly customized based on the customer’s research or clinical interests.” (source today’s trade release)
Quite often, either directly, indirectly, or reading between the lines? there is a reference to that expansion and new application areas?
Somehow I have a “hunch” that something new will come “to the fore” in the next 6-12 months? Licensing, a new partner, or something else big and POSITIVELY surprising.
It’s truly relentless, as Sepi K put it! JOY AND HAPPINESS to own!
When new orders seem to be coming in frequently, one could assume that funds have already appeared among the owners. Initially, Revenio, which recreated itself from the ruins of Done, was long almost entirely owned by small investors. After rising for a while, Revenio also started attracting institutions as owners. A similar situation is seen with Nexstim. The listing turned into a flop and funds disappeared, and now Nexstim, which has “recreated” itself, is starting to interest funds again. Small investors probably enjoy being among the first again.
Yep, one could assume so, but the ownership listing doesn’t support this change yet. Perhaps small cap fund managers have even better targets, yep yep.
It has also risen in recent months, to the extent that a professional managing the fund would likely see it as retail investor frenzy, which makes one think twice about jumping on board.
Easily so, but if Nexstim succeeds in getting new partners and the old ones succeed, the reward will be enormous. Currently, it is quite challenging for a larger investor to acquire a sufficient stake. I think that if someone were to acquire, for example, 300K shares, the price would rise sharply. Today’s trading volume was approximately 10K shares.
One can certainly buy an even larger amount and trust that the stock market operates efficiently, and at some price point, more shares will then become available for sale. We are still far from the prices at which investors knowledgeable about the company would want to divest themselves of their shares.
This stock has already exceeded even the wildest dreams of its potential. Few believed this would happen; it hasn’t been long since the stock could be bought for a little over two euros.
Reflecting on the sales of November-December in the previous two years and the fact that orders are now coming from a wide front, unlike before, it feels like the 20 euro mark will be surpassed very soon. I’d even guess by October.
Nexstim seems to be quite well featured in Brainlab’s presentation, see picture. Based on that one picture alone, it’s clear that Brainlab is seriously collaborating with Nexstim. Furthermore, the phrase “Brainlab and Nexstim join forces” is great; it specifically refers to a partnership, not just that we happen to sell this company’s devices. Oh wow
You’d think professionals would be able to calculate P/E ratios, even just a little, to estimate what they might be next year? The rise itself means nothing; it only matters what price what is being bought is at, compared to the estimation of its future.
That’s just it, if they do know how and conclude that it’s not worth joining at these prices. Inderes’s way of calculating shows how professionals tend to operate, a bit conservatively. And one has to admit that if the company’s market cap is 115M€ and H1/25 revenue is 4.5M€,
Well, that’s their problem. But in addition to revenue, there’s also profitability, meaning is it priced correctly if, for example, with 0.6e EPS and a price of 16 next year, the P/E ratio becomes 26. For a company whose revenue is growing by about 50% per year at the same time. For a company like Revenio, which isn’t really growing much anymore and whose profitability is a bit so-so, the P/E is over 40.
That’s exactly what I was thinking, that a professional doesn’t just put forward a figure for 2026 earnings that is the size of the 2025 H1 revenue on flimsy grounds.
Of course, everyone can roughly calculate this year’s result. Whether the EPS hits the mark with 0.05e accuracy is another matter entirely. But if the funds want realized facts, then they will get them next year in February. Fortunately, we ordinary folks don’t have such restrictions, so we can make decisions based on our own assessment
Here is my first quick projection for next year’s results. Only uncertainty is certain, but some general directions are already starting to emerge from it. Recurring revenue is likely higher than this estimate, as many devices that increase recurring revenue were sold at the end of last year and this year.
Equipment sales for the therapy business have also been forecasted with a 100% growth to the 2024 figures (this year, devices have been sold cumulatively 100% more in terms of units than by the end of October last year). I believe that sales of combination devices will start to pick up speed again now that sales permits for diagnostics are also in place.
Challenges are welcome and encouraged!
Edit. The text on the ‘purchases’ line stated that Brainlab would be excluded from the calculations, but in reality, it is also included.
It’s not really expensive when you compare it to this. Could @Antti_Siltanen provide similar estimates now based on already realized sales figures? At least I don’t quite understand such a big difference myself. What is weighing down Nexstim’s EPS so heavily in Inderes’ estimate vs. Kyhnykeisari’s estimate?
And again, I would like to better understand Inderes’ estimate.
I have also considered Brainlab’s annual sales of about 100 devices. But I find the assumption of an even distribution difficult to accept. If 83 devices were sold next year, and buyers are satisfied, then I believe more will be sold the following year. Therefore, I predict the number of devices will grow to around 100 over the next 3 years. What happens after that, I have not predicted. Something like this: 2026 - 50 devices, 2027 - 75, 2028 - 100.
